DXCM · NASDAQ
DexCom, Inc.
$77.95 -0.21 (-0.27%)
Company overview
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes and healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, which is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's product portfolio includes Dexcom G7, a next generation G7 CGM system. DexCom, Inc.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NASDAQ
- Market cap
- $29.4B
- Employees
- 10,200
- Headquarters
- San Diego, CA
- Website
- dexcom.com
- CEO
- Jacob Steven Leach
- Listed
- April 14, 2005
- P/E
- 32.48
- Dividend yield
- 0.00%
Company financials
- Revenue
- $4.8B
- Gross profit
- $3B
- Operating income
- $1B
- EBITDA
- $1.3B
- Net income
- $930M
- EPS
- $2.40
- Total assets
- $6.6B
- Total debt
- $1.4B
- Gross margin
- 61.84%
- Net margin
- 19.31%
- Earnings yield
- 3.08%
No product segmentation.
Showing FY 2025
DXCM
1D
NASDAQ
O79.90H80.49L77.11C78.32-1.94 (-2.42%)Vol10.79M